This presentation discusses Proxen Plus, a fixed-dose combination drug containing naproxen and esomeprazole. Proxen Plus is designed to release esomeprazole first in the stomach to block acid production, followed by release of enteric-coated naproxen in the small intestine. It is indicated for conditions requiring NSAID treatment like musculoskeletal disorders, where lowering gastric acidity can reduce risks. Studies show Proxen Plus is as effective as other NSAIDs for pain relief, while providing better gastrointestinal safety over long-term use up to one year. The presentation promotes Proxen Plus to rheumatologists, surgeons and other physicians as a convenient, cost-effective option for patients at risk of NSAID-associated ul

1. Welcome
to
the presentation
On

2. Every relationship starts
somewhere……

3. Combinations always does the best

4. Often Taking Naproxen Single is a
Danger

5. Naproxen Sodium+ Esomeprazole
Magnesium

6. Why Necessary

7. Dual Action, Dual Impact

8. Naproxen & Esomeprazole
 Modified-release tablet containing enteric-coated (gastro-
resistant) naproxen and film-coated esomeprazole.

9. Indications

10. Mechanism of Esomeprazole

11. Mechanism of Action of Naproxen
Sodium

12. NSAIDs Action

13. Naproxen Works on Selected
Areas of body

14. M/A of Proxen plus
• Proxen Plus is a fixed dose combination of the proton
pump inhibitor esomeprazole magnesium, with the non-
steroidal anti-inflammatory drug (NSAID) naproxen in a
single tablet. Proxen Plus has been developed as a
delayed release tablet whereby esomeprazole (20 mg) is
released first in the stomach, prior to the dissolution of
enteric-coated naproxen (500 mg) in the small intestine.
The mechanism of action of the naproxen, like that of
other NSAIDs, is not completely understood but may be
related to prostaglandin synthetase inhibition. By acting
specifically on the proton pump, esomeprazole blocks
the final step in acid production, thus reducing gastric
acidity.

15. Dosing Information
• One tablet to be swallowed whole twice
daily, taken 30 minutes before food.

16. Administration

17.  Indigestion ,impaired sense of taste
 Inflammation of sinuses
 Back pain, dizziness, cough,constipation
 Burning or discomfort of stomach, gas,
headache
Side Effects

18. Cautions

19. Global Leader’s Study

20. Why Not Omeprazole,
Why we combine Esomeprazole

21. Present Market Scenario
Products
Name Company
Market
Share Sales Growth LaunchingYear
DINOVO Beximco 1.25% 84,145,873 22.48% 2011
XENOLE Square 1.03% 69,058,731 7.74% 2012
Naprosyn
Plus Radiant 16.95%
145,535,325
25.06% 2012
NAPROX
PLUS Eskayef 3.33% 48,165,368 17.19% 2013
NAPRO-A-
PLUS ACME 3.39% 49,054,797 33.81% 2012

22. Brand Analysis
Brand Name Contains Dosage Form Manufacturer Price(Tk.)
DEMOVO 375
Naproxen sodium 375mg &
esomeprazole 20mg/tablet
Tablet
Delta Pharma
Limited
375mg x 24s pack:
192.00 MRP
DEMOVO 500
Naproxen sodium 500mg &
esomeprazole 20mg/tablet
Tablet
Delta Pharma
Limited
500mg x 16s pack:
160.00 MRP
DINOVO
375/20
Naproxen sodium 375mg &
esomeprazole 20mg/tablet
Tablet
Beximco
Pharmaceuticals
Ltd
375mg x 50s pack:
400.00 MRP
DINOVO
500/20
Naproxen sodium 500mg &
esomeprazole 20mg/tablet
Tablet
Beximco
Pharmaceuticals
Ltd
500mg x 50s pack:
500.00 MRP
NAPXON 375
Naproxen sodium 375mg &
esomeprazole 20mg/tablet
Tablet
Ziska
Pharmaceuticals
Ltd
375mg x 32s pack:
256.00 MRP
NAPXON 500
Naproxen sodium 500mg &
esomeprazole 20mg/tablet
Tablet
Ziska
Pharmaceuticals
Ltd
500mg x 32s pack:
320.00 MRP
NESO-375
Naproxen sodium 375mg &
esomeprazole 20mg/tablet
Tablet
Aristopharma
Ltd.
375mg x 40s pack:
320.00 MRP
NESO-500
Naproxen sodium 500mg &
esomeprazole 20mg/tablet
Tablet
Aristopharma
Ltd.
500mg x 40s pack:
400.00 MRP
PROGESIC 375
Naproxen sodium 375mg &
esomeprazole 20mg/tablet
Tablet
Incepta
Pharmaceuticals
Ltd
375mg x 30s pack:
240.00 MRP
PROGESIC 500
Naproxen sodium 500mg &
esomeprazole 20mg/tablet
Tablet
Incepta
Pharmaceuticals
Ltd
500mg x 28s pack:
280.00 MRP

23. Key promotional
Points
1) FDA approves this to treat Musculoskeletal Disorders
after vigorous Study
2) Comparative effectiveness and safety of Proxen Plus
against both meloxicam and celecoxib would be required
for the following outcomes:
*Pain
*Gastrointestinal outcomes
*Cardiovascular outcomes
3) 100% satisfactory for those patients who are at a risk of
NSAID-associated gastric and/or duodenal ulcers and
where lower doses of naproxen or other NSAIDs are not
sufficient.

24. Key promotional Points
• Safe for long term use up to one year.
• Convenient & cost effective.

25. Target Customers
• Rheumatologists
• Arthritis Specialist
• Orthopedics
• Surgeons
• Gastroenterologists
• Medicine Specialists
• GPs

27. Lowest dose can achieve the
goals

29. Thanks
Ashikur Rahman
Product Executive
PMD
MonicoPharma Limited